Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

L. Rimassa; E. Assenat; M. Peck-Radosavljevic; M. Pracht; V. Zagonel; P. Mathurin; E. Rota Caremoli; C. Porta; B. Daniele; L. Bolondi; V. Mazzaferro; W. Harris; N. Damjanov; D. Pastorelli; M. Reig; J. Knox; F. Negri; J. Trojan; C. López López; N. Personeni; T. Decaens; M. Dupuy; W. Sieghart; G. Abbadessa; B. Schwartz; M. Lamar; T. Goldberg; D. Shuster; A. Santoro; J. Bruix

doi:10.1016/S1470-2045(18)30146-3

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

L. Rimassa, E. Assenat, M. Peck-Radosavljevic, M. Pracht, V. Zagonel, P. Mathurin, E. Rota Caremoli, C. Porta, B. Daniele, L. Bolondi, V. Mazzaferro, W. Harris, N. Damjanov, D. Pastorelli, M. Reig, J. Knox, F. Negri, J. Trojan, C. López López, N. PersoneniT. Decaens, M. Dupuy, W. Sieghart, G. Abbadessa, B. Schwartz, M. Lamar, T. Goldberg, D. Shuster, A. Santoro, J. Bruix

Research output: Contribution to journal › Article › peer-review

Original language	Undefined/Unknown
Pages (from-to)	682-693
Number of pages	12
Journal	The Lancet Oncology
Volume	19
Issue number	5
DOIs	https://doi.org/10.1016/S1470-2045(18)30146-3
Publication status	Published - 2018

Access to Document

10.1016/S1470-2045(18)30146-3

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044869480&doi=10.1016%2fS1470-2045%2818%2930146-3&partnerID=40&md5=2b14ddb916fb9091fa9314b63de6087b

Cite this

Rimassa, L., Assenat, E., Peck-Radosavljevic, M., Pracht, M., Zagonel, V., Mathurin, P., Rota Caremoli, E., Porta, C., Daniele, B., Bolondi, L., Mazzaferro, V., Harris, W., Damjanov, N., Pastorelli, D., Reig, M., Knox, J., Negri, F., Trojan, J., López López, C., ... Bruix, J. (2018). Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. The Lancet Oncology, 19(5), 682-693. https://doi.org/10.1016/S1470-2045(18)30146-3

Rimassa, L, Assenat, E, Peck-Radosavljevic, M, Pracht, M, Zagonel, V, Mathurin, P, Rota Caremoli, E, Porta, C, Daniele, B, Bolondi, L, Mazzaferro, V, Harris, W, Damjanov, N, Pastorelli, D, Reig, M, Knox, J, Negri, F, Trojan, J, López López, C, Personeni, N, Decaens, T, Dupuy, M, Sieghart, W, Abbadessa, G, Schwartz, B, Lamar, M, Goldberg, T, Shuster, D, Santoro, A & Bruix, J 2018, 'Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study', The Lancet Oncology, vol. 19, no. 5, pp. 682-693. https://doi.org/10.1016/S1470-2045(18)30146-3

@article{06193f0b1a984b6b8434934efbe88b03,

title = "Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study",

author = "L. Rimassa and E. Assenat and M. Peck-Radosavljevic and M. Pracht and V. Zagonel and P. Mathurin and {Rota Caremoli}, E. and C. Porta and B. Daniele and L. Bolondi and V. Mazzaferro and W. Harris and N. Damjanov and D. Pastorelli and M. Reig and J. Knox and F. Negri and J. Trojan and {L{\'o}pez L{\'o}pez}, C. and N. Personeni and T. Decaens and M. Dupuy and W. Sieghart and G. Abbadessa and B. Schwartz and M. Lamar and T. Goldberg and D. Shuster and A. Santoro and J. Bruix",

note = "cited By 24",

year = "2018",

doi = "10.1016/S1470-2045(18)30146-3",

language = "Non definita",

volume = "19",

pages = "682--693",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "5",

}

TY - JOUR

T1 - Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

AU - Rimassa, L.

AU - Assenat, E.

AU - Peck-Radosavljevic, M.

AU - Pracht, M.

AU - Zagonel, V.

AU - Mathurin, P.

AU - Rota Caremoli, E.

AU - Porta, C.

AU - Daniele, B.

AU - Bolondi, L.

AU - Mazzaferro, V.

AU - Harris, W.

AU - Damjanov, N.

AU - Pastorelli, D.

AU - Reig, M.

AU - Knox, J.

AU - Negri, F.

AU - Trojan, J.

AU - López López, C.

AU - Personeni, N.

AU - Decaens, T.

AU - Dupuy, M.

AU - Sieghart, W.

AU - Abbadessa, G.

AU - Schwartz, B.

AU - Lamar, M.

AU - Goldberg, T.

AU - Shuster, D.

AU - Santoro, A.

AU - Bruix, J.

N1 - cited By 24

PY - 2018

Y1 - 2018

U2 - 10.1016/S1470-2045(18)30146-3

DO - 10.1016/S1470-2045(18)30146-3

M3 - Articolo

SN - 1470-2045

VL - 19

SP - 682

EP - 693

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 5

ER -